Biolight Life Sciences Ltd. · TASE:BOLT
Biolight Life Sciences — Investor Presentation (July 2023)
22 slides from Biolight Life Sciences's investor presentation, July 2023
Slide 1: Corporate Presentation
dite BIOLIGHT Corporate Presentation
Slide 2: The sole entity in Israel that invests solely in ophthalmic diseases
Ht tet The sole entity in Israel that invests 3355 BIOLIGHT eee imeme en cee Lid. solely in the growing space of : ophthalmic diseases Company assets at the end of 2022: NIS 150 Million | 1 foe 7 Portfolio Companies situated Companies in advanced stages (Detailed below) Approximately NIS 18 Million
Slide 3: Eye disease patient populations
340M Dry eye syndrome 146M Diabetic retinopathy 80M Glaucoma 190M Age-related Macular degeneration (AMD) And this is only a small sample from a variety of diseases that affect billions of individuals worldwide 7¢BlO
Slide 4: Today's Challenges and Unmet Needs
Today's Challenges and Unmet Needs ° Aging population ° Prevalence of eye disease rising * Insufficient eye doctors in relation to population growth ° Fear of losing eyesight (blindness) Tomorrow's Solutions --- ° Early detection 0 * Better and personalized drugs 0 * Improved devices for procedure a
Slide 5: Eye market growth forecast
Eye market growth forecast Average annual growth forecast for the eye market in the U.S. (drugs and medical device) Ophthalmology Drugs Market U.S. Ophthalmic Drugs Market size. by drug class, 2020 - 2030 (USD Billion) 6 5% U.S. Market CAGR. a O 2022 -2030 2020 2021 2022 2023 2024 2025 2026 2027 202
Slide 6: Holding Chart
Holding Chart s¥ BIOLIGHT Life Sciences Ltd cam Life Sciences Ltd. Subsidiaries : Affiliates / #:peripherex 36% VC approach - Held companies © BELKIN 4%
Slide 7: DiagnosTear: diagnosing front-of-the-eye diseases
* An ophthalmologist or a primary care doctor must have effective, accurate tools for diagnosing front-of-the-eye diseases The Problem: D | a en O sTe ar * Identifying conjunctivitis (Red Eye): Infections in the front of the eye caused by bacteria or viruses such as adenovirus, herpes, or allergic T
Slide 8: Visual Sciences: glaucoma implant
The Problem: A significant part of patients suffering from glaucoma are not complying with the medication treatment on a timely manner, causing an increase in intraocular pressure and the progression of the disease which can lead to vision loss The Solution: A biodegradable sub-conjunctival implant
Slide 9: Lipicare: Ocular.D dry eye drops
The Problem: Dry eye syndrome and a syndrome known as Digital Eye Strain are common conditions characterized by dryness and eye fatigue resulting also from prolonged exposure to blue light radiation emitted from digital and computer screens The Solution: Eye drops formulated with a nano-emulsion enr
Slide 10: OphRx: drug delivery technology
The Problem: Increasing the penetrability and improving the tolerance of drug O 0 Dp h Ry delivery to both the front and back of the eye The Solution: The Product . Eye drops containing high dosage of Cyclosporine is currently in Phase | human clinical trial phase OphRx technology, based on nanostru
Slide 11: Tear biomarkers for retinal diseases
The Problem: Considering the retina's crucial role in light absorption, converting it into nerve signals, and the initial processing of the visual input, any disease that impairs the function of the retina can lead to significant damage and even vision loss. Early diagnosis and prediction of the dis
Slide 12: Affiliated and held Companies
Affiliated and held Companies Company Summary Product Image Potential Develops artificial intelligence (Al) solutions for a variety of retinal diseases AEYE Received FDA approval for its Al product that was developed in combination with a desktop camera for autonomous detection of moderate to severe
Slide 13: Anticipated events of Subsidiaries
Anticipated events of Subsidiaries DiagnosTear Visual sciences LIPICARE PHARMACEUTICALS ©O OphRx a¥ BIOLIGHT ©) Completion of a clinical trial in India focused on dry eye POC in humans for red eye. Merger and listing on the Canadian Stock Exchange On-Line sales in the UK and Germany Completion of cl
Slide 14: Anticipated events of held and affiliated companies
Anticipated events of held companies and Affiliated AEYVEHealth Pharma tw Tarsiéf see the future O BELKIN oe Sanoculis Novel Glaucoma Trestment peripherex a¥ BIOLIGHT US launch and partnership agreements Obtaining the results of a Phase III clinical trial in humans Obtaining FDA approval for monitor
Slide 15: Summary of BioLight's assets & investments
Summary of BioLight’s assets & investments in its subsidiary and affiliated companies as of December 31, 2022 (in NIS): 17,625 Including short-term deposits and investment in tradable shares Estimated based on BioLight's holdings rate, pre-money, in Elcam medical transaction 44,338 Upon filling in C
Slide 16: Summary of BioLight's assets & investments
Summary of BioLight’s assets & investments in as of December 31, 2022 (in NIS) Tarsier Pharma Cost 6,537 Cost 5,915 Cost Cost 20,929 Estimated based on BioLight's holdings rate at the company’s valuation (pre-money) in the last investment round Value (the amount in the financial statements is approx
Slide 17: Cash and investment value
106,755 43,861 Cash and investment value in Subsidiaries and Affiliates Investment value in Held Companies 150,616 Assets value 7
Slide 18: Highly Experienced Management Team
Highly Experienced Management Team 00d & Israel Makov Yaacov Michlin Yifftach Biel Karin Gurevitz Chairman of the Board CEO CFO Vice President, fin] fin] Legal Counsel ox# BIO
Slide 19: Scientific Advisory Board
Scientific Advisory Board Dr. Ron Neumann BioLight's Chief Medical Officer (CMO), A leading expert ophthalmologist, specializing in inflammatory eye disease a¥ BIOLIGHT Prof. Anat Loewenstein Chairwoman of the Department of Ophthalmology at Ichilov Sourasky Medical Center & Vice Dean of Faculty, at
Slide 20: Main Shareholders
Main Shareholders [TAsE: BoLT] 7é BIO Dilip Shanghvi (Owner of Sun Pharma) 14% 9% Dan Oren (Owner Dexcel Pharma )
Slide 21: Forward looking information
Forward looking information This presentation was prepared by BioLight Life Sciences Ltd. ("BioLight") and contains summary information only. It does not include a detailed and/or complete description of BioLight, its subsidiaries, and holdings (collectively, the Company’), its activities or forecas
Slide 22: Thank You
333388 BIOLIGHT @@e@ Life Sciences Ltd THANK YOU E-mail: BioLight@bio-light.co.il Website: http://bio-light.co.il
BioLight Life Sciences — Investor Presentation (July 2023) on 6ix